drugset / Trial / NCT04382352
B002 in Patients With HER2-positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety and tolerability characteristics of B002 in patients with HER2-positive recurrent or metastatic breast cancer. The dose-limiting toxicity (DLT) was assessed and the maximum tolerated dose (MTD) was explored.
Timeline
- Start
- 2019-05-28
- Primary completion
- 2022-04-26
- Completion
- 2022-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B002 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | B002 | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | B002 | Monoclonal antibody | 12 mg/kg | Intravenous |
| Subject | B002 | Monoclonal antibody | 16 mg/kg | Intravenous |
| Subject | B002 | Monoclonal antibody | 20 mg/kg | Intravenous |